Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200

References

• HarrisNLRoncheseFThe role of B7 costimulation in T-cell immunityImmunol Cell Biol19997730431110457196
   PubMed Web of Science ®Google Scholar
• SearlePFYoungLSImmunotherapy II: antigens, receptors and costimulationCancer Metastasis Rev1996153293499034595
   PubMed Web of Science ®Google Scholar
• SpaapenRBlomenVvan VeelenPIdentification of potential immunotherapeutic targets in antigen presentation and costimulation networksJ Immunother Cancer20142Suppl 3P126
   Google Scholar
• MajTWeiSWellingTZouWT cells and costimulation in cancerCancer J20131947348224270346
   PubMed Web of Science ®Google Scholar
• AnsariMJSalamaADChitnisTThe programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) miceJ Exp Med2003198636912847137
   PubMed Web of Science ®Google Scholar
• TivolEABorrielloFSchweitzerANLynchWPBluestoneJASharpeAHLoss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4Immunity199535415477584144
   PubMed Web of Science ®Google Scholar
• ChambersCASullivanTJAllisonJPLymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cellsImmunity199778858959430233
   PubMed Web of Science ®Google Scholar
• ZhangJZhangMJiangWB7-H4 gene polymorphisms are associated with sporadic breast cancer in a Chinese Han populationBMC Cancer2009939419903360
   PubMed Web of Science ®Google Scholar
• LinesJLPantaziEMakJVISTA is an immune checkpoint molecule for human T cellsCancer Res2014741924193224691993
   PubMed Web of Science ®Google Scholar
• MonneyLSabatosCAGagliaJLTh1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune diseaseNature200241553654111823861
   PubMed Web of Science ®Google Scholar
• NishimuraHNoseMHiaiHMinatoNHonjoTDevelopment of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptorImmunity19991114115110485649
   PubMed Web of Science ®Google Scholar
• OkazakiTOkazakiIMWangJPD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in miceJ Exp Med201120839540721300912
   PubMed Web of Science ®Google Scholar
• KormanAJPeggsKSAllisonJPCheckpoint blockade in cancer immunotherapyAdv Immunol20069029733916730267
   PubMed Web of Science ®Google Scholar
• WolchokJDYangASWeberJSImmune regulatory antibodies: are they the next advance?Cancer J20101631131720693841
   PubMed Web of Science ®Google Scholar
• PardollDMThe blockade of immune checkpoints in cancer immunotherapyNat Rev Cancer20121225226422437870
   PubMed Web of Science ®Google Scholar
• LizéeGOverwijkWWRadvanyiLGaoJSharmaPHwuPHarnessing the power of the immune system to target cancerAnnu Rev Med201364719023092383
   PubMed Web of Science ®Google Scholar
• NiLDongCNew checkpoints in cancer immunotherapyImmunol Rev2017276526528258699
   PubMed Web of Science ®Google Scholar
• ChambersCAKuhnsMSEgenJGAllisonJPCTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapyAnnu Rev Immunol20011956559411244047
   PubMed Web of Science ®Google Scholar
• EgenJGKuhnsMSAllisonJPCTLA-4: new insights into its biological function and use in tumor immunotherapyNat Immunol2002361161812087419
   PubMed Web of Science ®Google Scholar
• O’DaySJHamidOUrbaWJTargeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignanciesCancer20071102614262718000991
   PubMed Web of Science ®Google Scholar
• PhanGQYangJCSherryRMCancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanomaProc Natl Acad Sci U S A20031008372837712826605
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med201036371172320525992
   PubMed Web of Science ®Google Scholar
• WeberJImmune checkpoint proteins: a new therapeutic paradigm for cancer–preclinical background: CTLA-4 and PD-1 blockadeSemin Oncol20103743043921074057
   PubMed Web of Science ®Google Scholar
• KwekSSDaoVRoyRDiversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patientsJ Immunol20121893759376622956585
   PubMed Web of Science ®Google Scholar
• MayKFJrGulleyJLDrakeCGDranoffGKantoffPWProstate cancer immunotherapyClin Cancer Res2011175233523821700764
   PubMed Web of Science ®Google Scholar
• WeberJSKählerKCHauschildAManagement of immune-related adverse events and kinetics of response with ipilimumabJ Clin Oncol2012302691269722614989
   PubMed Web of Science ®Google Scholar
• NishinoMRamaiyaNHHatabuHHodiFSMonitoring immune-checkpoint blockade: response evaluation and biomarker developmentNat Rev Clin Oncol20171465566828653677
   PubMed Web of Science ®Google Scholar
• SantegoetsSJStamAGLougheedSMT cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatmentCancer Immunol Immunother20136224525622878899
   PubMed Web of Science ®Google Scholar
• LesterhuisWJSalmonsJNowakAKSynergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunityPLoS One201384e6189523626745
   PubMed Web of Science ®Google Scholar
• WuXLiJConnollyEMCombined anti-VEGF and anti-CTLA-4 therapy elicits humoral immunity to Galectin-1 which is associated with favorable clinical outcomesCancer Immunol Res2017544645428473314
   PubMed Web of Science ®Google Scholar
• HuangRYFrancoisAMcGrayARMiliottoAOdunsiKCompensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancerOncoimmunology201661e124956128197366
   PubMed Web of Science ®Google Scholar
• BalarAVWeberJSPD-1 and PD-L1 antibodies in cancer: current status and future directionsCancer Immunol Immunother20176655156428213726
   PubMed Web of Science ®Google Scholar
• BrahmerJRDrakeCGWollnerIPhase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlatesJ Clin Oncol2010283167317520516446
   PubMed Web of Science ®Google Scholar
• FuJMalmIJKadayakkaraDKLevitskyHPardollDKimYJPreclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumorsCancer Res2014744042405224812273
   PubMed Web of Science ®Google Scholar
• NomanMZDesantisGJanjiBPD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activationJ Exp Med201421178179024778419
   PubMed Web of Science ®Google Scholar
• GeYXiHJuSZhangXBlockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID miceCancer Lett201333625325923523609
   PubMed Web of Science ®Google Scholar
• TopalianSLDrakeCGPardollDMTargeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunityCurr Opin Immunol20122420721222236695
   PubMed Web of Science ®Google Scholar
• HerbstRSBaasPKimDWPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet20163871540155026712084
   PubMed Web of Science ®Google Scholar
• RittmeyerABarlesiFWaterkampDAtezolizumab versus docetaxel in patients with previously treated nonsmall-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialLancet201738925526527979383
   PubMed Web of Science ®Google Scholar
• TanvetyanonTGrayJEAntoniaSJPD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?Expert Opin Biol Ther201717330531228064556
   PubMed Web of Science ®Google Scholar
• HegdeUPMukherjiBCurrent status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapiesCancer Immunol Immunother Epub2017511
   Web of Science ®Google Scholar
• YuPSteelJCZhangMMorrisJCWaldmannTASimultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma modelClin Cancer Res2010166019602820924130
   PubMed Web of Science ®Google Scholar
• TerabeMRobertsonFCClarkKBlockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapyOncoimmunology201765e130861628638730
   PubMed Web of Science ®Google Scholar
• WongKKBannermanBChesnyESpanerDDGorczynskiRMSoluble CD200 is critical to engraft chronic lymphocytic leukemia cells in immunocompromised miceCancer Res2012724931494322875025
   PubMed Web of Science ®Google Scholar
• GorczynskiRMClarkDAErinNKhatriIRole of CD200 expression in regulation of metastasis of EMT6 tumor cells in miceBreast Cancer Res Treat2011130496021165772
   PubMed Web of Science ®Google Scholar
• ZhouJMahoneyKMGiobbie-HurderASoluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockadeCancer Immunol Res2017548049228522460
   PubMed Web of Science ®Google Scholar
• DempkeWCMFenchelKUciechowskiPDaleSPSecond- and third-generation drugs for immuno-oncology treatment-the more the better?Eur J Cancer201774557228335888
   PubMed Web of Science ®Google Scholar
• LinesJLSempereLFBroughtonTWangLNoelleRVISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapyCancer Immunol Res2014251051724894088
   PubMed Web of Science ®Google Scholar
• LiuJYuanYChenWImmune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responsesProc Natl Acad Sci U S A20151126682668725964334
   PubMed Web of Science ®Google Scholar
• BögerCBehrensHMKrügerSRöckenCThe novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: a future perspective for a combined gastric cancer therapy?Oncoimmunology201764e129321528507801
   PubMed Web of Science ®Google Scholar
• DasMZhuCKuchrooVKTim-3 and its role in regulating anti-tumor immunityImmunol Rev20172769711128258697
   PubMed Web of Science ®Google Scholar
• DougallWCKurtulusSSmythMJAndersonACTIGIT and CD96: new checkpoint receptor targets for cancer immunotherapyImmunol Rev201727611212028258695
   PubMed Web of Science ®Google Scholar
• LiuXKwonHLiZFuYXIs CD47 an innate immune checkpoint for tumor evasion?J Hematol Oncol20171011228077173
   PubMed Web of Science ®Google Scholar
• GorczynskiRMChenZLeeLYuKHuJAnti-CD200R ameliorates collagen-induced arthritis in miceClin Immunol200210425626412217336
   PubMed Web of Science ®Google Scholar
• GorczynskiRMCD200 and its receptors as targets for immunoregulationCurr Opin Investig Drugs20056483488
   PubMedGoogle Scholar
• WongKKKhatriIShahaSSpanerDEGorczynskiRMThe role of CD200 in immunity to B cell lymphomaJ Leukoc Biol20108836137220442224
   PubMed Web of Science ®Google Scholar
• RygielTPKarnamGGoverseGCD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumorOncogene2012312979298822020332
   PubMed Web of Science ®Google Scholar
• MemarianANourizadehMMasoumiFUpregulation of CD200 is associated with Foxp3+ regulatory T cell expansion and disease progression in acute myeloid leukemiaTumour Biol20133453154223179394
   PubMedGoogle Scholar
• PallaschCPUlbrichSBrinkerRHallekMUgerRAWendtnerCMDisruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockadeLeuk Res20093346046418838168
   PubMed Web of Science ®Google Scholar
• PohSLLinnYCImmune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blastsCancer Immunol Immunother20166552553626961084
   PubMed Web of Science ®Google Scholar
• SivaAXinHQinFOlteanDBowdishKSKretz-RommelAImmune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200Cancer Immunol Immunother20085798799618060403
   PubMed Web of Science ®Google Scholar
• SunHXuJHuangMCD200R, a co-inhibitory receptor on immune cells, predicts the prognosis of human hepatocellular carcinomaImmunol Lett201617810511327562325
   PubMed Web of Science ®Google Scholar
• MoertelCLXiaJLaRueRCD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapyJ Immunother Cancer2014214625598973
   PubMedGoogle Scholar
• RingEKMarkertJMGillespieGYFriedmanGKCheckpoint proteins in pediatric brain and extracranial solid tumors: opportunities for immunotherapyClin Cancer Res20172334235027836863
   PubMed Web of Science ®Google Scholar
• XiongZAmpudia-MesiasEShaverRHorbinskiCMMoertelCLOlinMRTumor-derived vaccines containing CD200 inhibit immune-activation: implications for immunotherapyImmunotherapy201681059107127485078
   PubMed Web of Science ®Google Scholar
• RygielTPMeyaardLCD200R signaling in tumor tolerance and inflammation: a tricky balanceCurr Opin Immunol20122423323822264927
   PubMed Web of Science ®Google Scholar
• ErinNPodnosATanrioverGBidirectional effect of CD200 on breast cancer development and metastasis, with ultimate outcome determined by tumor aggressiveness and a cancer-induced inflammatory responseOncogene201534293860387025263452
   PubMed Web of Science ®Google Scholar
• GorczynskiRMChenZKhatriIPodnosAYuKCure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signalingBreast Cancer Res Treat201314227128224166280
   PubMed Web of Science ®Google Scholar
• GorczynskiRMChenZErinNKhatriIPodnosAComparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapyPLoS One2014911e11359725409195
   PubMed Web of Science ®Google Scholar
• GorczynskiRPodnosAKosOOyedeleAZhuFKhatriISignificance of soluble CD200 in plasma and serum of human breast cancer patientsInt Med Rev2016210
   Google Scholar
• WangWLiuJHeYMcLeodHLProspect for immune checkpoint blockade: dynamic and comprehensive monitorings pave the wayPharmacogenomics2017181299130428745931
   PubMed Web of Science ®Google Scholar
• EliasRMoralesJPresleyCCheckpoint Inhibitors for non-small cell lung cancer among older adultsCurr Oncol Rep2017196228755314
   PubMed Web of Science ®Google Scholar
• DasteADomblidesCGross-GoupilMImmune checkpoint inhibitors and elderly people: a reviewEur J Cancer201768155166
   Web of Science ®Google Scholar
• MarroneKAFordePMCancer immunotherapy in older patientsCancer J20172321922228731944
   PubMed Web of Science ®Google Scholar